ClinicalTrials.gg
RecruitingNCT06507787SEM EDIT-BUpdated Nov 3, 2026

Evaluation of the Impact of the EDIT-B® Blood Test on the Health Status of Patients Presenting a Major Depressive Episode. Clinical Utility and Medico-Economic Aspects

An interventional study of EDIT-B test and EDIT-B test (without giving result) in Bipolar Disorder and Major Depressive Disorder, sponsored by Alcediag. Recruiting at 7 sites in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Alcediag · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.
Updated Nov 3, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 104 studies in Bipolar Disorder with a site in France — 34 open to participants now, 38 under way, 1 of them phase 3. Bipolar Disorder · France.

Planned enrollment
15th of 79
450 · median 170
Started
2025
with 6 others
No phase
56 of 104
22 open now
Primary completion
2028-04
later than 28 of 37 live
Registered
88th of 104
by date

Among the 104 studies in Bipolar Disorder with a site in France, this one is the 15th largest by planned enrollment of the 79 interventional ones that give a count, is one of 7 that started in 2025, is one of 56 with no phase, reaches primary completion later than 28 of the 37 other live ones, and was the 88th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

34 of the 104 studies in Bipolar Disorder with a site in France are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies in Bipolar Disorder with a site in France, or all of them as a file.
02

Study summary

Depression is one of the most common mental disorders, affecting nearly 10% of men and 20% of women worldwide. It is associated with a significant increase in mortality, mainly due to suicidal behavior. The Diagnostic and Statistical Manual of Mental Disorders (DSM) defines a Major Depressive Episode (MDE) by a combination of at least five different symptoms, with at least one depressed mood or loss of interest. MDEs can occur in isolation or as part of Major Depressive Disorder (MDD) or bipolar disorder (BD). Bipolar disorders affect 2% of the world's population and are defined by episodes of mania (Type I BD) or hypomania (Type II BD) alternating with episodes of depression and periods of remission.

Depression occurring whether in the context of BD or MDD is defined with the same clinical criteria. However, the pharmacological treatments are different in the two groups. In particular, antidepressants prescribed without a thymoregulator in bipolar patients can lead to a worsening of the episode, favoring suicidal behavior or a manic turn.

The average interval between the onset of BD symptoms and appropriate diagnosis is estimated to be approximately 7 years, which delays appropriate management and treatment and increases the risk of suicide.

Biological markers able to differentiate between the different types of depression were lacking before the advent of EDIT-B®; one of the main objectives of this research is to measure the clinical impact of the use of EDIT-B® in the short and medium term on the management of patients with BD and major depression. The health economic aspect will also be considered.

In total, 450 patients in two different groups (EDIT-B® group and control group) will be recruited over a study timeline of 24 months. Study participation is over 6 months with 4 visits.

03

Conditions studied

  • Bipolar Disorder
  • Major Depressive Disorder

Keywords

  • Clinical Utility
  • Bipolar Disorder
  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a MDE, moderate to severe (DSM V criteria and MADRS score ≥19)
  • Age between 18 and 65 years, gender indifferent
  • Benefitting from health insurance coverage
  • Having signed an and agreed to follow the study protocol to completion
  • Patients for whom there is doubt regarding a bipolar disorder diagnosis, and/or presenting one or more of the following criteria:

    • More than 3 episodes of MDE in personal medical history
    • Psychotic symptoms
    • Family history of bipolar disorder
    • Onset of the first MDE before the age of 25
    • Atypical symptoms or mixed features during depressive episodes
    • Addiction
    • Personal history of suicide attempts
    • Resistance to antidepressants
    • Postpartum depression within 6 months of birth

Exclusion criteria

Exclusion Criteria:

  • Depression in the context of schizophrenia or autism spectrum disorder
  • Patient with a well-established diagnosis of bipolar disorder
  • Patients who is already receiving a mood stabilizer
  • Severe somatic diseases that may interfere with the follow-up or associated with treatments at risk of secondary manic decompensation
  • Neurodegenerative diseases
  • Pregnant women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    With EDIT-B test result

    The investigator will have the EDIT-B® test result to guide the treatment strategy.

    Diagnostic Test: EDIT-B test

  • Placebo comparator
    Without EDIT-B test result

    The investigator will not have the EDIT-B® test result, but EDIT-B® is still performed on participants in the beginning of the study.

    Diagnostic Test: EDIT-B test (without giving result)

Interventions

  • Diagnostic testEDIT-B test

    EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%. For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions. The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact.

  • Diagnostic testEDIT-B test (without giving result)

    EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%. For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions. THE RESULT OF THE TEST WILL NOT BE GIVEN TO THE PARTICIPANT BEFORE THE END OF THE STUDY. The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact.

06

What researchers measure

Primary outcomes

  1. Improvement in depressive symptoms between inclusion and 15-16 weeks visit.

    Clinically meaningful improvement at week 15-16 in depressive symptoms, defined as a 6-point or greater reduction in MADRS total score from baseline, without a manic switch, defined as an increase in the YMRS total score above 11 from baseline, measured using a composite endpoint.

    Time frame: 4 months (from inclusion visit to 15-16 weeks visit)

07

Study locations

3 of 7 sites recruiting
  • CH Erstein
    Erstein, France
    Not yet recruiting
  • AP-HP Corentin Celton
    Issy-les-Moulineaux, France
    Not yet recruiting
    • Nicolas Hoertel, Pr · Contactnicolas.hoertel@aphp.fr · +33 1 58 00 44 21
    • Nicolas Hoertel, Pr · Principal investigator
  • Etablissement Public de Santé Mentale (EPSM) 74
    La Roche-sur-Foron, France
    Not yet recruiting
    • Rocco De Filippis, Pr · Contactdefilippis-r@ch-epsm74.fr · +33 749121443
    • Rocco De Filippis, Pr · Principal investigator
  • Clinique Villa des Roses
    Lyon, France
    Recruiting
  • Clinique Le Clos Montaigne
    Montrond-les-Bains, France
    Recruiting
    • Christophe Aimo, Dr · Contactchristophe.aimo@inicea.fr · +33 4 77 36 01 00
    • Christophe Aimo, Dr · Principal investigator
  • GHU Paris Psychiatrie et Neurosciences
    Paris, France
    Recruiting
  • Clinique Médicale de Ville d'Avray
    Ville-d'Avray, France
    Not yet recruiting
    • Jérôme Dischamps · Contactjdischamps@wanadoo.fr · +33147094314
    • Jérôme Dischamps · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Apr 2028, 38 months after the start.

Of 363 interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 38 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion May 2026 → Apr 2028 and completion May 2027 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2024
First posted
Jul 18, 2024
StartActual
Feb 3, 2025
Primary completionEst.
Apr 2028was May 2026
CompletionEst.
Jun 2028was May 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Clinique Médicale de Ville d'Avray · Ville-d'Avray, France
Show 1 removed
  • Clinique Médicale de Ville d'Avray · Ville d'Avray, France
Nov 3, 2026
Primary completion
May 2026→Apr 2028
Nov 3, 2026
Study completion
May 2027→Jun 2028
Nov 3, 2026
Contact
Study contact changed: d•••@alcediag-alcen.com · •••0700→m•••@alcediag-alcen.com · •••0700. See the current contact
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    1 site added, 1 site removed
    Show site
    • Clinique Médicale de Ville d'Avray · Ville-d'Avray, France
    Show 1 removed
    • Clinique Médicale de Ville d'Avray · Ville d'Avray, France
    Primary completion May 2026→Apr 2028
    Study completion May 2027→Jun 2028
    Contact Study contact changed: d•••@alcediag-alcen.com · •••0700→m•••@alcediag-alcen.com · •••0700. See the current contact
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06507787
Lead sponsor
Alcediag
Collaborators
BPIfrance, Synlab Holding Deutschland GmbH, GHU Paris Psychiatrie et Neurosciences, CH Erstein, AP-HP Corentin-Celton, Clinique Villa des Roses, Clinique Le clos Montaigne, Clinique Médicale de Ville d'Avray, EPSM 74
Responsible party
Sponsor
First posted
Jul 18, 2024
Start date
Feb 3, 2025
Primary completion
Apr 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Mary Menhem, PharmD, MSc
Contact
mary.menhem@alcediag-alcen.com
+33788970700

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion